Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Amgen reports strong Q4 growth amid expanding product sales and biotech innovations Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio… byPallavi MadhirajuFebruary 5, 2025